The protein tyrosine phosphatase receptor type J is regulated by the pVHL-HIF axis in clear cell renal cell carcinoma

Journal of Pathology

Volumn 229, Issue 4, 2013, Pages 525-534

  Casagrande, Silvia ^a   Ruf, Melanie ^a   Rechsteiner, Markus ^a   Morra, Laura ^a   Brun Schmid, Sonja ^a   Von Teichman, Adriana ^a   Krek, Wilhelm ^b   Schraml, Peter ^a   Moch, Holger ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b ETH ZURICH   (Switzerland)

Author keywords

PTPRJ; RCC; VHL HIF pathway

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 2ALPHA; MESSENGER RNA; PROTEIN TYROSINE PHOSPHATASE RECEPTOR TYPE J; RNA; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; CANCER CELL; CANCER PROGNOSIS; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN SITU HYBRIDIZATION; KIDNEY CARCINOMA; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; WESTERN BLOTTING;

BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IN SITU HYBRIDIZATION; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MODELS, MOLECULAR; POLYMORPHISM, GENETIC; RECEPTOR-LIKE PROTEIN TYROSINE PHOSPHATASES, CLASS 3; RNA, MESSENGER; RNA, NEOPLASM; SEQUENCE ANALYSIS, DNA; TISSUE ARRAY ANALYSIS; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 84874101235     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4107     Document Type: Article

References (46)

1. Banks RE, Tirukonda P, Taylor C, et al,. Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res 2006; 66: 2000-2011.
2. Frew IJ, Krek W,. Multitasking by pVHL in tumour suppression. Curr Opin Cell Biol 2007; 19: 685-690.
3. Gossage L, Eisen T,. Alterations in VHL as potential biomarkers in renal-cell carcinoma. Nature Rev Clin Oncol 2010; 7: 277-288.
4. Bluyssen HA, Lolkema MP, van Beest M, et al,. Fibronectin is a hypoxia-independent target of the tumor suppressor VHL. FEBS Lett 2004; 556: 137-142.
5. Esteban MA, Tran MG, Harten SK, et al,. Regulation of E-cadherin expression by VHL and hypoxia-inducible factor. Cancer Res 2006; 66: 3567-3575.
6. Luu VD, Boysen G, Struckmann K, et al,. Loss of VHL and hypoxia provokes PAX2 up-regulation in clear cell renal cell carcinoma. Clin Cancer Res 2009; 15: 3297-3304.
7. Roe JS, Kim H, Lee SM, et al,. p53 stabilization and transactivation by a von Hippel-Lindau protein. Mol Cell 2006; 22: 395-405.
8. Boysen G, Bausch-Fluck D, Thoma CR, et al,. Identification and functional characterization of pVHL-dependent cell surface proteins in renal cell carcinoma. Neoplasia 2012; 14: 535-546.
9. Honda H, Inazawa J, Nishida J, et al,. Molecular cloning, characterization, and chromosomal localization of a novel protein-tyrosine phosphatase, HPTP eta. Blood 1994; 84: 4186-4194.
10. Balavenkatraman KK, Jandt E, Friedrich K, et al,. DEP-1 protein tyrosine phosphatase inhibits proliferation and migration of colon carcinoma cells and is upregulated by protective nutrients. Oncogene 2006; 25: 6319-6324.
11. Jandt E, Denner K, Kovalenko M, et al,. The protein-tyrosine phosphatase DEP-1 modulates growth factor-stimulated cell migration and cell-matrix adhesion. Oncogene 2003; 22: 4175-4185.
12. Kellie S, Craggs G, Bird IN, et al,. The tyrosine phosphatase DEP-1 induces cytoskeletal rearrangements, aberrant cell-substratum interactions and a reduction in cell proliferation. J Cell Sci 2004; 117: 609-618.
13. Trapasso F, Iuliano R, Boccia A, et al,. Rat protein tyrosine phosphatase eta suppresses the neoplastic phenotype of retrovirally transformed thyroid cells through the stabilization of p27(Kip1). Mol Cell Biol 2000; 20: 9236-9246.
14. Trapasso F, Yendamuri S, Dumon KR, et al,. Restoration of receptor-type protein tyrosine phosphatase eta function inhibits human pancreatic carcinoma cell growth in vitro and in vivo. Carcinogenesis 2004; 25: 2107-2114.
15. Ruivenkamp C, Hermsen M, Postma C, et al,. LOH of PTPRJ occurs early in colorectal cancer and is associated with chromosomal loss of 18q12-21. Oncogene 2003; 22: 3472-3474.
16. Ruivenkamp CA, van Wezel T, Zanon C, et al,. Ptprj is a candidate for the mouse colon-cancer susceptibility locus Scc1 and is frequently deleted in human cancers. Nature Genet 2002; 31: 295-300.
17. Tarcic G, Boguslavsky SK, Wakim J, et al,. An unbiased screen identifies DEP-1 tumor suppressor as a phosphatase controlling EGFR endocytosis. Curr Biol 2009; 19: 1788-1798.
18. Kovalenko M, Denner K, Sandstrom J, et al,. Site-selective dephosphorylation of the platelet-derived growth factor beta-receptor by the receptor-like protein-tyrosine phosphatase DEP-1. J Biol Chem 2000; 275: 16219-16226.
19. Grazia Lampugnani M, Zanetti A, Corada M, et al,. Contact inhibition of VEGF-induced proliferation requires vascular endothelial cadherin, beta-catenin, and the phosphatase DEP-1/CD148. J Cell Biol 2003; 161: 793-804.
20. Palka HL, Park M, Tonks NK,. Hepatocyte growth factor receptor tyrosine kinase met is a substrate of the receptor protein-tyrosine phosphatase DEP-1. J Biol Chem 2003; 278: 5728-5735.
21. Mertz KD, Demichelis F, Kim R, et al,. Automated immunofluorescence analysis defines microvessel area as a prognostic parameter in clear cell renal cell cancer. Hum Pathol 2007; 38: 1454-1462.
22. Jung M, Ramankulov A, Roigas J, et al,. In search of suitable reference genes for gene expression studies of human renal cell carcinoma by real-time PCR. BMC Mol Biol 2007; 8: 47.
23. Theurillat JP, Zurrer-Hardi U, Varga Z, et al,. Distinct expression patterns of the immunogenic differentiation antigen NY-BR-1 in normal breast, testis and their malignant counterparts. Int J Cancer 2008; 122: 1585-1591.
24. Schraml P, Frew IJ, Thoma CR, et al,. Sporadic clear cell renal cell carcinoma but not the papillary type is characterized by severely reduced frequency of primary cilia. Mod Pathol 2009; 22: 31-36.
25. Metzen E, Stiehl DP, Doege K, et al,. Regulation of the prolyl hydroxylase domain protein 2 (phd2/egln-1) gene: identification of a functional hypoxia-responsive element. Biochem J 2005; 387: 711-717.
26. Thoma CR, Frew IJ, Hoerner CR, et al,. pVHL and GSK3beta are components of a primary cilium-maintenance signalling network. Nature Cell Biol 2007; 9: 588-595.
27. Rechsteiner MP, von Teichman A, Nowicka A, et al,. VHL gene mutations and their effects on hypoxia inducible factor HIFα: identification of potential driver and passenger mutations. Cancer Res 2011; 71: 5500-5511.
28. Nickerson ML, Jaeger E, Shi Y, et al,. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res 2008; 14: 4726-4734.
29. Brauch H, Weirich G, Brieger J, et al,. VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation. Cancer Res 2000; 60: 1942-1948.
30. Herman JG, Latif F, Weng Y, et al,. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A 1994; 91: 9700-9704.
31. Hu CJ, Wang LY, Chodosh LA, et al,. Differential roles of hypoxia-inducible factor 1α (HIF-1α) and HIF-2α in hypoxic gene regulation. Mol Cell Biol 2003; 23: 9361-9374.
32. Raval RR, Lau KW, Tran MG, et al,. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 2005; 25: 5675-5686.
33. Mazure NM, Chauvet C, Bois-Joyeux B, et al,. Repression of α-fetoprotein gene expression under hypoxic conditions in human hepatoma cells: characterization of a negative hypoxia response element that mediates opposite effects of hypoxia inducible factor-1 and c-Myc. Cancer Res 2002; 62: 1158-1165.
34. Narravula S, Colgan SP,. Hypoxia-inducible factor 1-mediated inhibition of peroxisome proliferator-activated receptor alpha expression during hypoxia. J Immunol 2001; 166: 7543-7548.
35. Lee KJ, Lee KY, Lee YM,. Downregulation of a tumor suppressor RECK by hypoxia through recruitment of HDAC1 and HIF-1α to reverse HRE site in the promoter. Biochim Biophys Acta 2010; 1803: 608-616.
36. Iuliano R, Le Pera I, Cristofaro C, et al,. The tyrosine phosphatase PTPRJ/DEP-1 genotype affects thyroid carcinogenesis. Oncogene 2004; 23: 8432-8438.
37. Iuliano R, Palmieri D, He H, et al,. Role of PTPRJ genotype in papillary thyroid carcinoma risk. Endocr Relat Cancer 2010; 17: 1001-1006.
38. Mita Y, Yasuda Y, Sakai A, et al,. Missense polymorphisms of PTPRJ and PTPN13 genes affect susceptibility to a variety of human cancers. J Cancer Res Clin Oncol 2010; 136: 249-259.
39. Iuliano R, Trapasso F, Le Pera I, et al,. An adenovirus carrying the rat protein tyrosine phosphatase eta suppresses the growth of human thyroid carcinoma cell lines in vitro and in vivo. Cancer Res 2003; 63: 882-886.
40. Keane MM, Lowrey GA, Ettenberg SA, et al,. The protein tyrosine phosphatase DEP-1 is induced during differentiation and inhibits growth of breast cancer cells. Cancer Res 1996; 56: 4236-4243.
41. Minner S, Rump D, Tennstedt P, et al,. Epidermal growth factor receptor protein expression and genomic alterations in renal cell carcinoma. Cancer 2012; 118: 1268-1275.
42. Moch H, Sauter G, Buchholz N, et al,. Epidermal growth factor receptor expression is associated with rapid tumor cell proliferation in renal cell carcinoma. Hum Pathol 1997; 28: 1255-1259.
43. Drucker B, Bacik J, Ginsberg M, et al,. Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma. Invest New Drugs 2003; 21: 341-345.
44. Rowinsky EK, Schwartz GH, Gollob JA, et al,. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 2004; 22: 3003-3015.
45. Lynch TJ, Bell DW, Sordella R, et al,. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
46. Becker KF, Mack H, Schott C, et al,. Extraction of phosphorylated proteins from formalin-fixed cancer cells and tissues. Open Pathol J 2008; 2: 46-52.